[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212 547 9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.", "fullTimeEmployees": 72, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend", "age": 43, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 864335, "exercisedValue": 0, "unexercisedValue": 6398299}, {"maxAge": 1, "name": "Dr. Eric  Adler M.D.", "age": 50, "title": "Chief Medical Officer & Head of Research", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 623400, "exercisedValue": 0, "unexercisedValue": 586874}, {"maxAge": 1, "name": "Ms. Jenny R. Robertson J.D.", "age": 49, "title": "Chief Business & Legal Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 617900, "exercisedValue": 0, "unexercisedValue": 94692}, {"maxAge": 1, "name": "Dr. Ronald G. Crystal M.D.", "title": "Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kyle  Rasbach Ph.D., Pharm.D.", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jose Manuel Otero Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 53, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  McHenry", "title": "VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.03, "open": 4.06, "dayLow": 3.87, "dayHigh": 4.22, "regularMarketPreviousClose": 4.03, "regularMarketOpen": 4.06, "regularMarketDayLow": 3.87, "regularMarketDayHigh": 4.22, "payoutRatio": 0.0, "forwardPE": -1.400722, "volume": 148188, "regularMarketVolume": 148188, "averageVolume": 251625, "averageVolume10days": 341550, "averageDailyVolume10Day": 341550, "bid": 3.84, "ask": 3.92, "bidSize": 1, "askSize": 1, "marketCap": 128340704, "fiftyTwoWeekLow": 3.84, "fiftyTwoWeekHigh": 19.5, "fiftyDayAverage": 5.9534, "twoHundredDayAverage": 10.273975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -13361234, "profitMargins": 0.0, "floatShares": 21688616, "sharesOutstanding": 33077500, "sharesShort": 1879532, "sharesShortPriorMonth": 2237640, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.056799997, "heldPercentInsiders": 0.01285, "heldPercentInstitutions": 1.06488, "shortRatio": 8.36, "shortPercentOfFloat": 0.0636, "impliedSharesOutstanding": 33077500, "bookValue": 4.215, "priceToBook": 0.9205219, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -86596000, "trailingEps": -12.64, "forwardEps": -2.77, "enterpriseToEbitda": 0.144, "52WeekChange": -0.7346939, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 3.88, "targetHighPrice": 28.0, "targetLowPrice": 16.0, "targetMeanPrice": 22.28571, "targetMedianPrice": 23.0, "recommendationMean": 1.42857, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 157020000, "totalCashPerShare": 4.749, "ebitda": -92728000, "totalDebt": 10403000, "quickRatio": 5.855, "currentRatio": 5.946, "debtToEquity": 7.467, "returnOnAssets": -0.51050997, "returnOnEquity": -1.07206, "grossProfits": -63935000, "freeCashflow": -38439876, "operatingCashflow": -66806000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "LXEO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Lexeo Therapeutics, Inc.", "shortName": "Lexeo Therapeutics, Inc.", "corporateActions": [], "regularMarketTime": 1740171149, "exchange": "NGM", "messageBoardId": "finmb_625814286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketPrice": 3.88, "regularMarketChangePercent": -3.7267103, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1699018200000, "regularMarketChange": -0.1500001, "regularMarketDayRange": "3.87 - 4.22", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 251625, "fiftyTwoWeekLowChange": 0.0400002, "fiftyTwoWeekLowChangePercent": 0.010416719, "fiftyTwoWeekRange": "3.84 - 19.5", "fiftyTwoWeekHighChange": -15.62, "fiftyTwoWeekHighChangePercent": -0.8010256, "fiftyTwoWeekChangePercent": -73.46939, "marketState": "REGULAR", "epsTrailingTwelveMonths": -12.64, "epsForward": -2.77, "epsCurrentYear": -3.08841, "priceEpsCurrentYear": -1.25631, "fiftyDayAverageChange": -2.0734, "fiftyDayAverageChangePercent": -0.34827158, "twoHundredDayAverageChange": -6.3939753, "twoHundredDayAverageChangePercent": -0.62234676, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-11-03", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "displayName": "Lexeo Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]